The unveiling of encouraging topline findings from their pivotal Phase 3 study evaluating ANX005 for the treatment of Guillain-Barré syndrome (GBS) has caused a considerable
Annexon, Inc. (NASDAQ: ANNX) witnessed an upward trajectory in its stock performance during the after-market session on Thursday, culminating in a notable 5.91% surge in
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.